Antimicrobial Effect of Oxazolidinones and Its Synergistic Effect with Bedaquiline Against Mycobacterium abscessus Complex

References

• Lin C, Russell C, Soll B., et al. Increasing Prevalence of Nontuberculous Mycobacteria in Respiratory Specimens from US-Affiliated Pacific Island Jurisdictions. Emerg Infect Dis. 2018;24(3):485–491. doi:10.3201/eid2403.171301
   PubMed Web of Science ®Google Scholar
• Raats D, Brode SK, Mehrabi M, Marras TK. Increasing and More Commonly Refractory Mycobacterium avium Pulmonary Disease, Toronto, Ontario, Canada. Emerg Infect Dis. 2022;28(8):1589–1596. doi:10.3201/eid2808.220464
   PubMed Web of Science ®Google Scholar
• Jin P, Dai J, Guo Y, et al. Genomic Analysis of Mycobacterium abscessus Complex Isolates from Patients with Pulmonary Infection in China. Microbiol Spectr. 2022;10(4):e0011822. doi:10.1128/spectrum.00118-22
   PubMed Web of Science ®Google Scholar
• Santos A, Carneiro S, Silva A, Gomes JP, Macedo R. Nontuberculous Mycobacteria in Portugal: trends from the last decade. Pulmonology. 2022. doi:10.1016/j.pulmoe.2022.01.011
   Google Scholar
• Griffith DE, Aksamit T, Brown-Elliott BA, et al. An Official ATS/IDSA Statement: diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases. Am J Respir Crit Care Med. 2007;175(4):367–416. doi:10.1164/rccm.200604-571ST
   PubMed Web of Science ®Google Scholar
• Yoshida M, Sano S, Chien JY, et al. A novel DNA chromatography method to discriminate Mycobacterium abscessus subspecies and macrolide susceptibility. EBioMed. 2021;64:103187. doi:10.1016/j.ebiom.2020.103187
   PubMed Web of Science ®Google Scholar
• Kasperbauer SH, De Groote MA. The Treatment of Rapidly Growing Mycobacterial Infections. Clin Chest Med. 2015;36(1):67–78. doi:10.1016/j.ccm.2014.10.004
   PubMed Web of Science ®Google Scholar
• Daley CL, Iaccarino JM, Lange C, et al. Treatment of Nontuberculous Mycobacterial Pulmonary Disease: an Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. Eur Respir J. 2020;56(1):2000535. doi:10.1183/13993003.00535-2020
   PubMed Web of Science ®Google Scholar
• Bozdogan B, Appelbaum PC. Oxazolidinones: activity, mode of action, and mechanism of resistance. Int J Antimicrob Agents. 2004;23(2):113–119. doi:10.1016/j.ijantimicag.2003.11.003
   PubMed Web of Science ®Google Scholar
• Diekema DJ, Jones RN. Oxazolidinones. Drugs. 2000;59(1):7–16. doi:10.2165/00003495-200059010-00002
   PubMed Web of Science ®Google Scholar
• Shaw KJ, Barbachyn MR. The oxazolidinones: past, present, and future. Ann N Y Acad Sci. 2011;1241:48–70. doi:10.1111/j.1749-6632.2011.06330.x
   PubMed Web of Science ®Google Scholar
• Ruth MM, Sangen JJN, Remmers K, et al. A bedaquiline/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria. J Antimicrob Chemother. 2019;74(4):935–943. doi:10.1093/jac/dky526
   PubMed Web of Science ®Google Scholar
• Chew KL, Octavia S, Go J, et al. In vitro susceptibility of Mycobacterium abscessus complex and feasibility of standardizing treatment regimens. J Antimicrob Chemother. 2021;76(4):973–978. doi:10.1093/jac/dkaa520
   PubMed Web of Science ®Google Scholar
• Gil E, Sweeney N, Barrett V, et al. Bedaquiline as Treatment for Disseminated Nontuberculous Mycobacteria Infection in 2 Patients Co-Infected with HIV. Emerg Infect Dis. 2021;27(3):944–948. doi:10.3201/eid2703.202359
   PubMed Web of Science ®Google Scholar
• Huang L, Li H, Ren W, et al. Highly Discriminative Genotyping of Mycobacterium abscessus Complex Using a Set of Variable Number Tandem Repeats in China. Front Microbiol. 2022;1:12. doi:10.3389/fmicb.2021.802133
   Google Scholar
• Woods GL, Brown-Elliott BA, Conville PS, et al. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes. 2nd. Clinical and Laboratory Standards Institute;2011.
   Google Scholar
• Doern CD. When Does 2 Plus 2 Equal 5? A Review of Antimicrobial Synergy Testing. J Clin Microbiol. 2014;52(12):4124–4128. doi:10.1128/JCM.01121-14
   PubMed Web of Science ®Google Scholar
• Vesenbeckh S, Schönfeld N, Roth A, et al. Bedaquiline as a potential agent in the treatment of Mycobacterium abscessus infections. Eur Respir J. 2017;49(5):1700083. doi:10.1183/13993003.00083-2017
   PubMed Web of Science ®Google Scholar
• Brown-Elliott BA, Wallace RJ. In Vitro Susceptibility Testing of Bedaquiline against Mycobacterium abscessus Complex. Antimicrob Agents Chemother. 2019;63(2):e01919–18. doi:10.1128/AAC.01919-18
   PubMed Web of Science ®Google Scholar
• Pang Y, Zheng H, Tan Y, Song Y, Zhao Y. In Vitro Activity of Bedaquiline against Nontuberculous Mycobacteria in China. Antimicrob Agents Chemother. 2017;61(5):e02627–16. doi:10.1128/AAC.02627-16
   PubMed Web of Science ®Google Scholar
• Brown-Elliott BA, Wallace RJ. In Vitro Susceptibility Testing of Tedizolid against Nontuberculous Mycobacteria. J Clin Microbiol. 2017;55(6):1747–1754. doi:10.1128/JCM.00274-17
   PubMed Web of Science ®Google Scholar
• Kim TS, Choe JH, Kim YJ, et al. Activity of LCB01-0371, a Novel Oxazolidinone, against Mycobacterium abscessus. Antimicrob Agents Chemother. 2017;61(9):e02752–16. doi:10.1128/AAC.02752-16
   PubMed Web of Science ®Google Scholar
• Barbachyn MR, Ford CW. Oxazolidinone Structure–Activity Relationships Leading to Linezolid. Angew Chem Int Ed. 2003;42(18):2010–2023. doi:10.1002/anie.200200528
   PubMed Web of Science ®Google Scholar
• Locke JB, Finn J, Hilgers M, et al. Structure-Activity Relationships of Diverse Oxazolidinones for Linezolid-Resistant Staphylococcus aureus Strains Possessing the cfr Methyltransferase Gene or Ribosomal Mutations. Antimicrob Agents Chemother. 2010;54(12):5337–5343. doi:10.1128/AAC.00663-10
   PubMed Web of Science ®Google Scholar
• Wen S, Gao X, Zhao W, et al. Comparison of the in vitro activity of linezolid, tedizolid, sutezolid, and delpazolid against rapidly growing mycobacteria isolated in Beijing, China. Int J Infect Dis IJID off Publ Int Soc Infect Dis. 2021;109:253–260. doi:10.1016/j.ijid.2021.06.055
   PubMed Web of Science ®Google Scholar
• Kim S, Louie A, Drusano GL, et al. Evaluating the effect of clofazimine against Mycobacterium tuberculosis given alone or in combination with pretomanid, bedaquiline or linezolid. Int J Antimicrob Agents. 2022;59(2):106509. doi:10.1016/j.ijantimicag.2021.106509
   PubMed Web of Science ®Google Scholar
• Morita M, Gravel SP, Hulea L, et al. mTOR coordinates protein synthesis, mitochondrial activity and proliferation. Cell Cycle. 2015;14(4):473–480. doi:10.4161/15384101.2014.991572
   PubMed Web of Science ®Google Scholar